AEON Biopharma已发布其2025财年全年财务业绩报告。同时,公司重点通报了其ABP-450生物类似药项目的积极进展,包括正向的对比分析研究结果以及美国食品药品监督管理局(FDA)提供的反馈意见。
AEON Biopharma已发布其2025财年全年财务业绩报告。同时,公司重点通报了其ABP-450生物类似药项目的积极进展,包括正向的对比分析研究结果以及美国食品药品监督管理局(FDA)提供的反馈意见。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.